Updated guidance has been developed to inform clinicians prescribing and administering long-acting injectable buprenorphine (LAIB) preparations.
LAIB formulations currently registered in Australia are: Buvidal Weekly and Buvidal Monthly, manufactured by Camurus; and Sublocade, manufactured by Indivior. These products are available on the Pharmaceutical Benefits Scheme (PBS) under an s100 opioid-dependence listing.
The guidance is an update of the first (interim) NSW Clinical guidelines for use of depot buprenorphine (Buvidal and Sublocade) in the treatment of opioid dependence, published in 2019. The updated guidance was developed by Professors Nicholas Lintzeris and Adrian Dunlop, and Michelle Shulz. It incorporates clinical and consumer experience, research evidence, and updated product information for both LAIB formulations since the 2019 guideline.
Two versions are available:
The guides should be read in conjunction with the NSW Clinical Guidelines: Treatment of Opioid Dependence (noting that updates to this document are anticipated).
